Suppr超能文献

术前治疗的病理反应是壶腹和十二指肠腺癌的新型预后预测因子。

Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.

机构信息

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Ann Surg Oncol. 2017 Dec;24(13):3954-3963. doi: 10.1245/s10434-017-6098-6. Epub 2017 Oct 4.

Abstract

BACKGROUND

The prognostic impact of pathologic response to preoperative therapy on patients with duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) has not been established.

METHODS

A retrospective review of 266 patients who underwent curative resection for DA (n = 97) or AMPA (n = 169) during 1993-2015 was performed. For patients who underwent preoperative therapy, the pathologic response was systematically evaluated and classified as major (0-49% of viable residual tumor cells) or minor (≥ 50% of viable residual tumor cells). Uni- and multivariable analyses were performed to identify predictors of pathologic response and disease-specific survival (DSS).

RESULTS

For the 79 patients treated with preoperative therapy (DA: n = 34; AMPA: n = 45), concomitant use of radiation (80%, 67/79) was the sole independent predictor of major pathologic response (odds ratio [OR] 8.17; 95% confidence interval [CI] 1.85-58.2; P = 0.005). The patients with major pathologic response had a better 5-year DSS rate than the patients with minor pathologic response (DA: 65 vs 25%; P = 0.028; AMPA: 85 vs 43%; P = 0.016). In the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS (hazard ratio [HR] 2.88; 95% CI 1.41-5.98; P = 0.004). In the multivariable analysis of DSS for the entire cohort, pathologic stage 2 or lower was the sole predictor of better DSS.

CONCLUSION

The major pathologic response to preoperative therapy predicted improved DSS after resection of DA and AMPA and might represent a new prognosticator after resection of DA and AMPA.

摘要

背景

术前治疗的病理反应对十二指肠腺癌(DA)和壶腹腺癌(AMPA)患者的预后影响尚未确定。

方法

对 1993 年至 2015 年间接受根治性切除术的 266 例 DA(n=97)或 AMPA(n=169)患者进行了回顾性分析。对于接受术前治疗的患者,系统评估了病理反应并分为主要反应(存活肿瘤细胞的 0-49%)或次要反应(≥50%存活肿瘤细胞)。进行单变量和多变量分析以确定病理反应和疾病特异性生存(DSS)的预测因素。

结果

对于 79 例接受术前治疗的患者(DA:n=34;AMPA:n=45),同时使用放疗(80%,67/79)是主要病理反应的唯一独立预测因素(比值比[OR]8.17;95%置信区间[CI]1.85-58.2;P=0.005)。主要病理反应患者的 5 年 DSS 率优于次要病理反应患者(DA:65%比 25%;P=0.028;AMPA:85%比 43%;P=0.016)。在对 79 例接受术前治疗的患者进行的 DSS 多变量分析中,主要病理反应是 DSS 改善的唯一预测因素(风险比[HR]2.88;95%CI 1.41-5.98;P=0.004)。在整个队列的 DSS 多变量分析中,病理分期 2 期或更低是 DSS 更好的唯一预测因素。

结论

术前治疗的主要病理反应预测了 DA 和 AMPA 切除后的 DSS 改善,并且可能是 DA 和 AMPA 切除后的新预后因素。

相似文献

1
Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.
Ann Surg Oncol. 2017 Dec;24(13):3954-3963. doi: 10.1245/s10434-017-6098-6. Epub 2017 Oct 4.
2
Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.
Ann Surg Oncol. 2017 Jul;24(7):2031-2039. doi: 10.1245/s10434-017-5777-7. Epub 2017 Jan 25.
3
Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma.
J Surg Oncol. 2014 May;109(6):556-60. doi: 10.1002/jso.23529. Epub 2013 Dec 11.
4
Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
J Surg Oncol. 2014 Aug;110(2):156-62. doi: 10.1002/jso.23600. Epub 2014 Mar 12.
5
Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma.
Ann Surg Oncol. 2008 Nov;15(11):3178-86. doi: 10.1245/s10434-008-0099-4. Epub 2008 Aug 20.
7
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
JAMA Surg. 2019 Aug 1;154(8):706-714. doi: 10.1001/jamasurg.2019.1170.
8
Significance of pathologic response to preoperative therapy in pancreatic cancer.
Ann Surg Oncol. 2011 Dec;18(13):3601-7. doi: 10.1245/s10434-011-2086-4. Epub 2011 Sep 27.
10

引用本文的文献

1
Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review.
Ann Surg Oncol. 2024 Feb;31(2):792-803. doi: 10.1245/s10434-023-14531-y. Epub 2023 Nov 11.
2
Preoperative Misdiagnosis in Patients Undergoing Pancreatoduodenectomy.
J Clin Med. 2022 Dec 3;11(23):7200. doi: 10.3390/jcm11237200.
3
Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles.
J Clin Med. 2020 Dec 30;10(1):104. doi: 10.3390/jcm10010104.

本文引用的文献

2
Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.
Ann Surg Oncol. 2017 Jul;24(7):2031-2039. doi: 10.1245/s10434-017-5777-7. Epub 2017 Jan 25.
3
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.
J Gastrointest Surg. 2017 Jan;21(1):164-174. doi: 10.1007/s11605-016-3265-1. Epub 2016 Oct 24.
4
A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
Cancer Chemother Pharmacol. 2016 Oct;78(4):841-6. doi: 10.1007/s00280-016-3143-2. Epub 2016 Sep 1.
9
Predictors of Survival in Ampullary, Bile Duct and Duodenal Cancers Following Pancreaticoduodenectomy: a 10-Year Multicentre Analysis.
J Gastrointest Surg. 2015 Jul;19(7):1247-55. doi: 10.1007/s11605-015-2833-0. Epub 2015 May 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验